Cost-effectiveness analysis of budesonide/formoterol in the maintenance treatment and as-needed (Symbicort SMART®) versus salmeterol/fluticasone plus terbutaline in the treatment of persistent asthma in Spain;Análisis coste-efectividad de budesonida/formoterol en el tratamiento de mantenimiento y a demanda (Symbicort SMART®) frente a salmeterol/fluticasona más terbutalina, en el tratamiento del asma persistente en España

Pharmacoeconomics - Spanish Research Articles

Volumn 7, Issue 4, 2010, Pages 163-175

  Cisneros, Carolina ^a   Quiralte, Joaquín ^b   Capel, Margarita ^c   Casado, Miguel Ángel ^d   Mellstrom, Carl ^c  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c ASTRAZENECA   (United Kingdom)

^d Pharmacoeconomics and Outcomes Research Iberia (PORIB)   (Spain)

Author keywords

Asthma; Budesonide formoterol; Cost effectiveness analysis; Salmeterol fluticasone; Terbutaline

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; TERBUTALINE SULFATE;

ARTICLE; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; EMERGENCY WARD; HOSPITALIZATION; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MILD PERSISTENT ASTHMA; PRIORITY JOURNAL; SPAIN;

EID: 79952349423     PISSN: 1695405X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03321485     Document Type: Article

References (36)

1. Nieto A, Alvarez-Cuesta E, Boquete M, et al. The cost of asthma treatment in Spain and rationalizing the expense. J Investig Allergol Clin Immunol. 2001;11:139-48. (Pubitemid 34226377)
2. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol. 2001;107:3-8.
3. Andersson F, Borg S, Ståhl E. The impact of exacerbations on the asthmatic patient's preference scores. J Asthma 2003;40:615-23. (Pubitemid 37296149)
4. Borderías L, Zabaleta M, Riesco JA, et al. Cost and management of asthma exacerbations in Spanish hospitals (COAX study in hospital services). Arch Bronconeumol 2005; 41:313-21. (Pubitemid 41020577)
5. Braman SS. The global burden of asthma. Chest 2006;130(1 Suppl):4S-12S.
6. Martínez-Moragón E, Serra-Batllés J, De Diego A, et al. Coste económico del paciente asmático en España (estudio AsmaCost). Arch Bronconeumol 2009;45:481-6.
7. Fueyo A, Ruiz MA, Ancochea J, et al. Asthma control in Spain. Do season and treatment pattern matter? Respir Med 2007;101:919-24.
8. Rabe KF, Adachi M, Lai CK, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004;114:40-7. (Pubitemid 39022491)
9. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2008. Disponible en: http://www.ginasthma.org
10. Guía Española para el manejo del asma GEMA 2009. Disponible en: http://www.guiasalud.es/GPC/GPC-304-Asma-GEMA2009.pdf
11. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005;171:129-36.
12. Vogelmeier C, D'Urzo A, Pauwels R, et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?. Eur Respir J 2005;26:819-28. (Pubitemid 41632038)
13. Rabe KF, Atienza T, Magyar P, et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006;368:744-53. (Pubitemid 44279053)
14. Lundborg M, Wille S, Bjermer L, et al. Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: an efficacy and cost-effectiveness study. Curr Med Res Opin 2006;22:809-21. (Pubitemid 43875550)
15. Kuna P, Peters MJ, Manjra AI, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract. 2007;61:725-36. (Pubitemid 46587876)
16. Bousquet J, Boulet LP, Peters MJ, et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/ fluticasone. Respir Med 2007;101:2437-46. (Pubitemid 350010579)
17. Peters M. Single-inhaler combination therapy for maintenance and relief of asthma: a new strategy in disease management. Drugs 2009;69:137-50.
18. Johansson G, Andreasson EB, Larsson PE, et al. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics 2006;24:695-708. (Pubitemid 43998822)
19. Miller E, Sears MR, McIvor A, et al. Canadian economic evaluation of budesonide-formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Can Respir J 2007;14:269-75. (Pubitemid 47532871)
20. Price D, Wirén A, Kuna P. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy 2007;62:1189-98. (Pubitemid 47374022)
21. Miller E, FitzGerald JM. Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies - a Canadian economic evaluation. Can J Clin Pharmacol 2008;15:e165-76.
22. Sears MR, Boulet LP, Laviolette M, Fitzgerald JM, et al. Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma. Eur Respir J 2008;31:982-9.
23. Tamminen K, Laine J, Soini E, et al. Cost-effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland. Curr Med Res Opin 2008;24:3453-61.
24. Consejo General de Colegios de Farmacéuticos. Catálogo de Medicamentos. Consejo Plus 2009. Madrid: Disponible en: http://www.portalfarma. com
25. Oblikue Consulting. Base de datos sanitarios e-salud. Disponible en: http://www.oblikue.com/bddcostes/
26. Ministerio de Trabajo e Inmigración. Mercado de Trabajo en España (marzo 2009). Disponible en: http://www.inem.es/inem/ciudadano/ empleo/eures/pdf/EEE/ESPANA-MT-marzo-09.pdf
27. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327-40. (Pubitemid 27384638)
28. O'Byrne PM, Pedersen S, Lamm CJ, et al. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med 2009;179:19-24.
29. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma: Formoterol and Corticosteroids Establishing Therapy (FACET) International.Study Group. N Engl J Med 1997; 337:1405-11.
30. Partridge MR, van der Molen T, Myrseth SE, et al. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med. 2006;13:6-13.
31. Balanag VM, Yunus F, Yang PC, et al. Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Pulm Pharmacol Ther 2006;19:139-47.
32. Maneechotesuwan K, Essilfie-Quaye S, Meah S, et al. Formoterol attenuates neutrophilic airway inflammation in asthma. Chest 2005;128:1936-42. (Pubitemid 41507524)
33. Cleland J, Thomas M, Price D. Pharmacoeconomics of asthma treatment. Expert Opin Pharmacother 2003;4:311-8.
34. Goldfarb N, Weston C, Hartmann CW, Sikirica M, et al. Impact of appropriate pharmaceutical therapy for chronic conditions on direct medical costs and workplace productivity: a review of the literature. Dis Manag 2004;7:61-75. (Pubitemid 38436643)
35. Buxton MJ, Sullivan SD, Andersson LF, et al. Country-specific cost-effectiveness of early intervention with budesonide in mild asthma. Eur Respir J 2004;24:568-74. (Pubitemid 39406129)
36. Ställberg B, Ekström T, Neij F, et al. A real-life cost-effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respir Med 2008;102:1360-70.